Quanta Therapeutics

Quanta Therapeutics is a private biopharmaceutical company focused on the most prevalent and elusive targets in oncology RAS. Our vision is to develop novel small-molecule cancer drugs by selectively targeting protein-protein interactions critical to oncogenic RAS activity. Driving Quanta's success is our unique high-throughput platform, which applies second harmonic generation (SHG) optical technology to identify allosteric modulators of membrane-bound protein complexes. By applying innovative medicinal chemistry and its unique protein conformation detection technology, Quanta aims to advance differentiated next-generation RAS programs to address the paradigm of resistance in oncology targeted therapies.